[go: up one dir, main page]

AR116113A1 - Método para fabricar un compuesto tetracíclico - Google Patents

Método para fabricar un compuesto tetracíclico

Info

Publication number
AR116113A1
AR116113A1 ARP190102518A ARP190102518A AR116113A1 AR 116113 A1 AR116113 A1 AR 116113A1 AR P190102518 A ARP190102518 A AR P190102518A AR P190102518 A ARP190102518 A AR P190102518A AR 116113 A1 AR116113 A1 AR 116113A1
Authority
AR
Argentina
Prior art keywords
manufacturing
tetracyclic compound
carbonitrile
morpholin
piperidin
Prior art date
Application number
ARP190102518A
Other languages
English (en)
Inventor
Naoto HAMA
Hiroshi Fukuda
Akira Kawase
Hiroki Serizawa
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of AR116113A1 publication Critical patent/AR116113A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B61/00—Other general methods

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Esta se refiere a un método para fabricar 9-etil-6,6-dimetil-8-[4-(morfolin-4-il)piperidin-1-il]-11-oxo-6,11-dihidro-5H-benzo[b]carbazol-3-carbonitrilo, y es industrialmente preferible, lo que permite obtener una sustancia objetiva en alto rendimiento de manera más segura y fácil que con el método convencional.
ARP190102518A 2018-09-04 2019-09-03 Método para fabricar un compuesto tetracíclico AR116113A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018165313 2018-09-04

Publications (1)

Publication Number Publication Date
AR116113A1 true AR116113A1 (es) 2021-03-31

Family

ID=69722303

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102518A AR116113A1 (es) 2018-09-04 2019-09-03 Método para fabricar un compuesto tetracíclico

Country Status (18)

Country Link
US (1) US11939322B2 (es)
EP (1) EP3848361B1 (es)
JP (1) JP7167171B2 (es)
KR (1) KR102635225B1 (es)
CN (1) CN112585126B (es)
AR (1) AR116113A1 (es)
AU (1) AU2019337018B2 (es)
BR (1) BR112021001145A2 (es)
CA (1) CA3107270A1 (es)
ES (1) ES3010145T3 (es)
HR (1) HRP20250284T1 (es)
HU (1) HUE070227T2 (es)
IL (1) IL281079B2 (es)
MX (1) MX2021002311A (es)
PL (1) PL3848361T3 (es)
SG (1) SG11202100983XA (es)
TW (1) TWI825163B (es)
WO (1) WO2020050241A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023008735A (es) 2021-01-29 2023-08-01 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para el tratamiento de cancer pediatrico.
CN117024410A (zh) * 2023-08-15 2023-11-10 上海药坦药物研究开发有限公司 一种艾乐替尼中间体及其制备方法
WO2025067412A1 (zh) * 2023-09-28 2025-04-03 重庆博腾制药科技股份有限公司 一种抗肿瘤药物中间体的制备方法
CN120081779A (zh) * 2025-02-19 2025-06-03 江苏天士力帝益药业有限公司 一种阿来替尼杂质01a及其控制方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS506987B1 (es) 1970-02-17 1975-03-19
JPS4918630B1 (es) 1970-07-29 1974-05-11
JPS5859712U (ja) 1981-10-16 1983-04-22 ニチバン株式会社 ラベル貼付機
JPH0892090A (ja) 1994-07-26 1996-04-09 Tanabe Seiyaku Co Ltd 医薬組成物
DE69505470T2 (de) 1994-08-04 1999-05-12 F. Hoffmann-La Roche Ag, Basel Pyrrolocarbazol
JP3235840B2 (ja) 1996-05-01 2001-12-04 イーライ・リリー・アンド・カンパニー プロテインキナーゼｃのハロ置換阻害剤
RU2238937C2 (ru) 1998-12-24 2004-10-27 Фудзисава Фармасьютикал Ко., Лтд. Производные имидазола, фармацевтическая композиция и способ профилактики и/или лечения на их основе
CA2372032A1 (en) 1999-05-14 2000-11-23 Rodney W. Rickards Compounds and therapeutic methods
GB0030417D0 (en) 2000-12-13 2001-01-24 Pharma Mar Sa An anticancer lead compound isolated from a New Zealand ascidian
FR2841138B1 (fr) 2002-06-25 2005-02-25 Cll Pharma Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation
EP1603567A4 (en) 2003-02-28 2006-10-18 Inotek Pharmaceuticals Corp TETRACYCLIC BENZAMIDE DERIVATIVES AND METHOD OF USE THEREOF
ES2263862T3 (es) 2003-03-07 2006-12-16 Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Ensayo de quinasa de linfoma anaplasico, sus reactivos y composiciones.
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US7872014B2 (en) 2003-07-23 2011-01-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US7378414B2 (en) 2003-08-25 2008-05-27 Abbott Laboratories Anti-infective agents
CA2546117A1 (en) 2003-11-21 2005-06-16 Novartis Ag 1h-imidazoquinoline derivatives as protein kinase inhibitors
US7687524B2 (en) 2003-12-12 2010-03-30 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
WO2005092062A2 (en) 2004-03-19 2005-10-06 Myriad Genetics, Inc. Compounds for neurodegenerative disorders
EP1725530A1 (en) 2004-03-19 2006-11-29 Speedel Experimenta AG Organic compounds
US7973061B2 (en) 2004-03-31 2011-07-05 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
CA2569170A1 (en) 2004-06-02 2005-12-22 Pharmacyclics, Inc. Factor viia inhibitor
CA2578066C (en) 2004-08-26 2011-10-11 Pfizer Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
US7091202B2 (en) 2004-09-15 2006-08-15 Bristol-Myers Squibb Company 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators
GB0517329D0 (en) 2005-08-25 2005-10-05 Merck Sharp & Dohme Stimulation of neurogenesis
KR20080056288A (ko) 2005-11-07 2008-06-20 아이알엠 엘엘씨 Ｐｐａｒ 조절제로서의 화합물 및 조성물
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
MX2009004426A (es) 2006-10-23 2009-08-12 Cephalon Inc Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met.
CN101687873A (zh) 2007-04-17 2010-03-31 百时美施贵宝公司 具有稠合杂环的11β-羟基类固醇Ⅰ型脱氢酶抑制剂
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
CA2693901C (en) 2007-07-20 2015-12-29 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
JP5583592B2 (ja) 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション Ｉｄｏ阻害剤
US20110038898A1 (en) 2008-03-13 2011-02-17 Shuichi Yada Dissolution properties of drug products containing olmesartan medoxomil
KR20120034639A (ko) 2009-05-07 2012-04-12 아스트라제네카 아베 치환된 1-시아노에틸헤테로시클릴카르복스아미드 화합물 750
RS58855B1 (sr) 2009-06-10 2019-07-31 Chugai Pharmaceutical Co Ltd Tetraciklična jedinjenja
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
JP4918630B1 (ja) 2010-08-20 2012-04-18 中外製薬株式会社 ４環性化合物を含む組成物
JP5006987B2 (ja) 2010-11-22 2012-08-22 中外製薬株式会社 ４環性化合物を含む医薬
MX389105B (es) 2012-09-25 2025-03-20 Chugai Pharmaceutical Co Ltd Inhibidor de quinasas reordenadas durante la transfeccion (ret).
CN106456651A (zh) 2014-04-25 2017-02-22 中外制药株式会社 以高用量含有四环性化合物的制剂
KR20220042486A (ko) 2014-04-25 2022-04-05 추가이 세이야쿠 가부시키가이샤 4환성 화합물의 신규 결정
CN106456556A (zh) 2014-06-18 2017-02-22 豪夫迈·罗氏有限公司 包含非离子性表面活性剂的新型药物组合物
TWI718102B (zh) 2014-08-08 2021-02-11 日商中外製藥股份有限公司 ４環性化合物的非晶質體
CN104402862B (zh) 2014-11-12 2016-10-05 苏州明锐医药科技有限公司 艾立替尼的制备方法
US9573932B2 (en) * 2015-03-02 2017-02-21 Yong Xu Synthesis of intermediates in the preparation of ALK inhibitor
WO2017073706A1 (ja) 2015-10-30 2017-05-04 中外製薬株式会社 ジヒドロナフト［２，３－ｂ］ベンゾフラン誘導体
CN106928184B (zh) 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法
CN106928185B (zh) 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法
CN107033124B (zh) 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法

Also Published As

Publication number Publication date
PL3848361T3 (pl) 2025-07-07
MX2021002311A (es) 2021-04-28
EP3848361C0 (en) 2025-01-22
IL281079B1 (en) 2024-08-01
BR112021001145A2 (pt) 2021-04-20
EP3848361A1 (en) 2021-07-14
JPWO2020050241A1 (ja) 2021-08-30
CN112585126A (zh) 2021-03-30
US20220372025A1 (en) 2022-11-24
HRP20250284T1 (hr) 2025-04-25
EP3848361A4 (en) 2022-06-15
JP7167171B2 (ja) 2022-11-08
WO2020050241A1 (ja) 2020-03-12
HUE070227T2 (hu) 2025-05-28
ES3010145T3 (en) 2025-04-01
SG11202100983XA (en) 2021-03-30
TWI825163B (zh) 2023-12-11
TW202024050A (zh) 2020-07-01
KR102635225B1 (ko) 2024-02-07
CN112585126B (zh) 2024-05-07
KR20210053890A (ko) 2021-05-12
IL281079A (en) 2021-04-29
AU2019337018B2 (en) 2024-03-07
US11939322B2 (en) 2024-03-26
IL281079B2 (en) 2024-12-01
AU2019337018A1 (en) 2021-03-18
CA3107270A1 (en) 2020-03-12
EP3848361B1 (en) 2025-01-22

Similar Documents

Publication Publication Date Title
AR116113A1 (es) Método para fabricar un compuesto tetracíclico
CL2020002277A1 (es) Formas cristalinas de compuesto de triazolopirimidina (divisional 201803734)
CO2017006099A2 (es) Formas sólidas de un inhibidor ask1
LT3814348T (lt) Pakeistieji naftiridinono junginiai, naudotini kaip t ląstelių aktyvatoriai
SV2018005792A (es) Nuevos derivados piperidinilo sustituidos con hetero (arilo), un proceso para su preparacion y composiciones farmaceuticas que los contienen
MX2019011758A (es) Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma.
MX2017014809A (es) Amidas heterociclicas como inhibidores de cinasa.
EA201700207A1 (ru) Гетерофазный полипропилен с улучшенным балансом ударная прочность/жесткость, улучшенной текучестью в порошкообразной форме, пониженной эмиссией и низкой усадкой
CL2012002345A1 (es) Proceso para la preparacion de derivados de isoxazolina; mezcla que comprende dichos derivados; metodo de control de insectos , ácaros, nemátodos y/o moluscos que comprende un compuesto derivado de isoxazolina o una mezcla que lo comprenda.
JP2014078699A5 (es)
GB201207866D0 (en) Organic light emitting device and method
MX394304B (es) Acelerador de cemento pasivado.
EP3064997A4 (en) LAMINATE, KIT FOR THE MANUFACTURE OF ORGANIC SEMICONDUCTORS AND PAINT COMPOSITION FOR THE MANUFACTURE OF ORGANIC SEMICONDUCTORS
MX2021002220A (es) Forma cristalina de base libre de lorlatinib.
DOP2015000187A (es) Proceso de fabricación de vortioxetina
UY38841A (es) Composiciones para controlar parásitos
CL2019001694A1 (es) Compuestos de pirazolopirimidina y métodos de uso de los mismos.
AR101434A1 (es) Método para producir (r)-1,1,3-trimetil-4-aminoindano
BR112016007581A2 (pt) pigmentos à base de compostos de bismuto
CL2017001615A1 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2.
CO2020012574A2 (es) Método para la preparación de una 1,2,4-triazolona 2,4,5-trisustituida
MX2015010584A (es) Producción de cuero.
PE20181933A1 (es) Procedimiento para fabricar una lechada de cal apagada de gran finura y lechada de cal de gran finura obtenida con agua de proceso
AR112587A1 (es) Psicosa-6-fosfato fosfatasa, composición para producir d-psicosa que comprende la enzima y métodos para producir d-psicosa utilizando la enzima
MX2019000810A (es) Metodo de fabricacion de placa de nucleo.